Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of oral LOXO-305 in previously treated CLL/SLL or NHL
CTR20202574Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirtobrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), non-Hodgkin lymphoma (NHL), Waldenström macroglobulinemia (WM), diffuse large B-cell lymphoma (DLBCL), sponsored by Eli Lilly and Company. Started May 2021; status: completed.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)Waldenström macroglobulinemia (WM)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20202574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202574.